147118-39-6

Basic information

• Product Name: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate
• Synonyms: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate;ZD-6 ;(3R,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3-hydroxy-5-oxo-6-heptenoic acid methyl ester;Methyl 7-[4-(4-FLUOROPHENYL)-6-ISO-PROPYL-2-(N-METHYL-N-METHYLSULFONYLAMINO)PYRIMIDIN-5-YL] -(3R,5R)-DIHYDROXY-(E)-6-HEPTENATE;Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-Methyl-N-Methanesul fonylaMino) pyriMidin-5-y;(R,E)-Methyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-MethylMethylsulfonaMido)pyriMidin-5-yl)-3-hydroxy-5-oxohept-6-enoate;Methyl (+)-(3R)-7-[4-(4-fluorophenyl)- 6-isopropyl-2-(N-Methyl-NMethansulphonylaMino) pyriMidin-5-yl]-3-hydroxy-5-oxo- 6(E)-heptenoate;5-Oxorosuvastatin Methyl ester
• CAS NO: 147118-39-6
• Molecular Formula: C₂₃H₂₈FN₃O₆S
• Molecular Weight: 493.55
• EINECS: 1312995-182-4
• Mol File: 147118-39-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 701.68 °C at 760 mmHg
• Flash Point: 378.163 °C
• Appearance: /
• Density: 1.311
• Vapor Pressure: 1.15E-20mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.87±0.20(Predicted)
• CAS DataBase Reference: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(147118-39-6)
• EPA Substance Registry System: Methyl(+)-(3-R)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesul fonylamino) pyrimidin-5-yl]-3-hydroxy-5-oxo-6(E)-heptenoate(147118-39-6)

Safety Data

• Hazardous Substances Data: 147118-39-6(Hazardous Substances Data)

Usage

Uses

5-Oxorosuvastatin methyl ester is an intermediate in the synthesis of Rosuvasatatin (calcium salt: R700500), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that decreases high-sensitivity C-reactive protein (hsCRP) and cholesterol concentrations in the blood.

InChI:InChI=1/C23H28FN3O6S/c1-14(2)21-19(11-10-17(28)12-18(29)13-20(30)33-4)22(15-6-8-16(24)9-7-15)26-23(25-21)27(3)34(5,31)32/h6-11,14,18,29H,12-13H2,1-5H3/b11-10+/t18-/m1/s1

Upstream product

• 7664-39-3 hydrogen fluoride 
• 147118-38-5 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonamido)-pyrimidin-5-yl)-(3R)-3-tert-butyldimethylsiloxy-5-oxo-(E)-6-heptenoic acid methyl ester 
• 131466-61-0 (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester 
• 1350364-18-9 C₁₅H₂₈O₇Si 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 
• 109744-49-2 Hydrogen (3R)-1-methyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate 
• 91424-40-7 3-(tert-butyldimethylsilyloxy)glutaric anhydride 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 147118-28-3 ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-27-2 ethyl 4-(4-fluorophenyl)-2-(methylsulfanyl)-6-(propan-2-yl)-pyrimidine-5-carboxylate 
• 147118-32-9 5-ethoxycarbonyl-6-(4'-fluorophenyl)-4-isopropyl-2-(methylamino)pyrimidine 

Downstream Products

• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 1416820-70-6 rosuvastatin 1-naphthalen-1-yl-ethylamine salt 
• 1416820-71-7 rosuvastatin (R)-1-(1-naphthyl)ethylamine 
• 917805-74-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid-2-methylpropan-2-amine 
• 852820-97-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine 
• 1422619-13-3 7-[4-(4-fluorophenyl)-6-isopropyl-2(N-methyl-N-methanesulfonamido)pyrimidin-5-yl]-(3R)-3-hydroxy-5-carbonyl-6-(E)-heptenoic acid 
• 1197348-98-3 3-methylbutyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate 
• 287714-41-4 rosuvastatin 
• 1374771-96-6 rosuvastatin, S-benzylisothiourea salt 

Relevant articles and documents

Preparation process of rosuvastatin calcium preparation

The invention provides a preparation process of a rosuvastatin calcium preparation, and belongs to the technical field of pharmaceutical preparations. With (3R)-tert-butyldimethylsiloxy-5-oxy-6-triphenylphosphoranylidene methyl caproate and 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amino)pyridine-5-formaldehyde as initial raw materials, wittig reaction, deprotection reaction, chiral reduction reaction, hydrolysis reaction and purification are carried out so as to obtain a rosuvastatin calcium crude drug; then the rosuvastatin calcium crude drug is uniformly mixed with a diluent, a disintegrating agent, a stabilizing agent and a lubricant so as to obtain a mixture, and then the mixture is tabletted so as to obtain the rosuvastatin calcium preparation. The preparation process of the rosuvastatin calcium preparation disclosed by the invention has the advantages of simple operation, high yield, low cost and stable quality.

A rosuvastatin calcium impurity preparation method

The invention discloses a preparation method of a rosuvastatin calcium impurity. The target compound is produced from 4-(4-fluorophenyl)-6-isopropyl-2(N-methyl-methanesulfonylamino)pyrimidine-5-yl]-formaldehyde and methyl (3R)-3-t-butyldimethylsiloxy-5-carbonyl-6-(triphenylphosphinevinyl)caproate through a Witting reaction, HF deprotection, alkaline hydrolysis and an acidifying reaction. The method has the characteristics of short synthesis route, simple operation, convenient post-treatment, and high purity and high yield of the product. The method provides certain help for register reporting of rosuvastatin calcium, production middle control and improvement of the quality of rosuvastatin calcium.

PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM VIA NOVEL AMINE INTERMEDIATE

The present invention, relates to novel amine salts of rosuvastatin and its process for the preparation. Moreover, the present invention also relates to improved process for the preparation of rosuvastatin calcium, employing novel amine salts as an intermediate.